Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
28 hedge funds and large institutions have $249K invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
67% less capital invested
Capital invested by funds: $758K → $249K (-$509K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$68.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$1.65K |
| 3 |
GS
GTS Securities
New York
|
+$1.23K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$808 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$259 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$38.6K |
| 2 |
C
Chescapmanager
Baltimore,
Maryland
|
-$9.32K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$4.38K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
-$161 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$94 |
DNA.WS Hedge Fund Activity: Q2 2024 in Review
28 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q2 2024, worth a combined $249K — down 67% from $758K a quarter earlier.
Fund positioning in DNA.WS was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Cowen and Company, adding an estimated $68.8K. The largest seller was Morgan Stanley, cutting an estimated $38.6K.
- 28 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $249K of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q2 2024, down 67% quarter-over-quarter.
- 3 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q2 2024 and 3 closed out, a net change of 0 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q2 2024 was Cowen and Company, an estimated $68.8K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q2 2024 was Morgan Stanley, an estimated $38.6K sold.
Based on aggregated 13F filings for Q2 2024.